

## Literature Search Queries

MEDLINE (Dialog)

PubMed

### I. Search Period for Target Data: July 01, 2007–December 31, 2011

Patients: Limited to HCC (excluding animal studies)

Language: Limited to English, Japanese literature

\*Newly established CQs were searched from January 01, 1982 to December 31, 2011

### II. Search Queries

#### [Chapter 1] Prevention

- **CQ1 Does interferon therapy effectively prevent chronic hepatitis C infection from developing into cancer? [PubMed]**

#1 “Liver Neoplasms” [MH] AND “Interferons” [majr] AND 2007/7/1 : 2011/11/15 [dp] AND Eng [la] NOT “case reports” [pt]

#2 “Liver Neoplasms” [MH] AND “Interferons” [majr] AND 2007/7/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]

#3 #1 or #2

- **CQ2 Does liver support therapy effectively prevent HCC? [PubMed]**

#1 “Carcinoma, Hepatocellular/prevention and control” [MH] AND 2007/7/1 : 2011/11/15 [dp] AND Eng [la] NOT “case reports” [pt]

#2 “Carcinoma, Hepatocellular/prevention and control” [MH] AND 2007/7/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]

#3 #1 or #2

- **CQ3 Does antiviral therapy against chronic hepatitis B effectively prevent HCC? [PubMed]**

#1 “Liver Neoplasms” [MH] AND (“lamivudine” [tiab] OR “adefovir dipivoxil” [Supplementary Concept] OR adefovir [tiab] OR “tenofovir disoproxil” [Supplementary Concept] OR tenofovir [tiab] OR “entecavir” [Supplementary Concept] OR entecavir [tiab] OR 3TC [tiab] OR emtricitabine [Supplementary Concept] OR emtricitabine [tiab]) AND 2007/7/1 : 2011/11/15 [dp] AND

- Eng [la] NOT “case reports” [pt]
- #2 “Liver Neoplasms” [MH] AND (“lamivudine” [tiab] OR “adefovir dipivoxil” [Supplementary Concept] OR adefovir [tiab] OR “tenofovir disoproxil” [Supplementary Concept] OR tenofovir [tiab] OR “entecavir” [Supplementary Concept] OR entecavir [tiab] OR 3TC [tiab] OR emtricitabine [Supplementary Concept] OR emtricitabine [tiab]) AND 2007/7/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]
- #3 #1 or #2

## [Chapter 2] Diagnosis and Surveillance

### • **CQ4 Who are eligible candidates for surveillance? [PubMed]**

- #1 “Risk Factors” [MH] “Carcinoma, Hepatocellular” [majr] AND 2007/7/1 : 2011/11/15 [dp] AND Eng [la] NOT “case reports” [pt]
- #2 “Risk Factors” [MH] “Carcinoma, Hepatocellular” [majr] AND 2007/7/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]
- #3 #1 or #2

### • **CQ5 Does surveillance improve prognosis? [PubMed]**

### • **CQ6 What methods are used in surveillance? [PubMed]**

- #1 “Liver Neoplasms” [MH] AND (surveillance [tiab] OR screening [tiab]) AND 2007/7/1 : 2011/11/15 [dp] AND Eng [la] NOT “case reports” [pt]
- #2 “Liver Neoplasms” [MH] AND (surveillance [tiab] OR screening [tiab]) AND 2007/7/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]
- #3 #1 or #2

### • **CQ7 When examining atypical liver nodules using dynamic CT or dynamic MRI, what size (cm) lesions should be examined? [PubMed]**

- #1 “Liver Neoplasms” [MH] AND (biopsy [MH] OR hepatectomy [MH] OR pathology [MH] OR patholo\* [tiab] OR resection\* [tiab]) AND (“MRI” [tiab] OR “CT” [tiab] OR ultraso\* [tiab]) AND 2007/7/1 : 2011/11/15 [dp] AND Eng [la] NOT “case reports” [pt]
- #2 “Liver Neoplasms” [MH] AND (biopsy [MH] OR hepatectomy [MH] OR pathology [MH] OR patholo\* [tiab] OR resection\* [tiab]) AND (“MRI” [tiab] OR “CT” [tiab] OR ultraso\* [tiab]) AND 2007/7/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]
- #3 #1 or #2

### • **CQ8 Is it useful to measure two or more tumor markers for diagnosing HCC? [PubMed]**

- #1 “Liver Neoplasms” [MH] AND “sensitivity and specificity” [MH] AND (“AFP” [tiab] OR “alphaf\*” [tiab] OR “DCP” [tiab] OR des-gamma\* [tiab] OR desgamma\* [tiab] OR PIVKA\* [tiab] OR Glypican-3 [tiab] OR GP3 [tiab] OR “Tumor Markers, Biological” [MH]) AND 2007/7/1 : 2011/11/15 [dp] AND Eng [la] NOT “case reports” [pt]
- #2 “Liver Neoplasms” [MH] AND “sensitivity and specificity” [MH] AND (“AFP” [tiab] OR alphaf

\* [tiab] OR “DCP” [tiab] OR des-gamma\* [tiab] OR desgamma\* [tiab] OR PIVKA\* [tiab] OR Glypican-3 [tiab] OR GP3 [tiab] OR “Tumor Markers, Biological” [MH]) AND 2007/7/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]

#3 #1 or #2

• **CQ9 Is tumor marker measurement an effective post-treatment indicator for HCC? [PubMed]**

#1 “Liver Neoplasms/therapy” [majr] AND (“AFP” [tiab] OR alphaf\* [tiab] OR “DCP” [tiab] OR des-gamma\* [tiab] OR desgamma\* [tiab] OR PIVKA\* [tiab] OR “Tumor Markers, Biological” [MH]) AND 2007/7/1 : 2011/11/15 [dp] AND Eng [la] NOT “case reports” [pt]

#2 “Liver Neoplasms/therapy” [majr] AND (“AFP” [tiab] OR alphaf\* [tiab] OR “DCP” [tiab] OR des-gamma\* [tiab] OR desgamma\* [tiab] OR PIVKA\* [tiab] OR “Tumor Markers, Biological” [MH]) AND 2007/7/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]

#3 #1 or #2

• **CQ10 What are the best tests for diagnosing early-stage HCC in patients with cirrhosis? [MEDLINE]**

S1 LIVER CIRRHOSIS! OR (LIVER OR LIVERS OR HEPATIC) (3N) CIRRHO? OR CHRONIC? (3N) LIVER (2W) (DISEASE? OR DISORDER?)

S2 (WELL () DIFFERENTI? OR SMALL? OR HYPOVASCULAR? OR ADENOMATOUS? (3N) HYPERPLASI? OR DYSPLASTI? (3N) NODUL?) /TI

S3 (BORDERLIN? OR NODUL?) /TI

S4 INTERNATIONAL? (3N) CONSENS? (3N) GROUP? (3N) HEPATOCEL? () NEOPLAS?

S5 FOCAL NODULAR HYPERPLASIA!

S6 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S7 EARLY (4N) (CARCINOM? OR HCC OR HEPATOM? OR NEOPLASM? OR CANCER? OR TUMOR? OR TUMOUR? OR HAEPATOM? OR HCCS)

S8 DISEASE PROGRESSION!

S9 DI/DE OR US/DE OR RA/DE OR RI/DE OR DIAGNOSTIC IMAGING!

S10 CT OR ULTRASONO? OR ULTRASONIC? OR NMR OR MRI OR IMAGE? OR IMAGING?

S11 OUTCOME? /TI

S12 SENSITIVI? OR ACCURAC? OR SPECIFICI? OR ROC

S13 (S1/DE OR S1/TI OR S2 OR S3 OR S4 OR S5) \* (S6+S7+S8) \* (S9+S10)

S14 S13 \* (LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?) /TI AND S11

S15 (DIAGNOS? OR IDENTI? OR DETECT? OR ASSESS? OR EVALUAT? OR MANAGE?) /TI

S16 (LIVER? OR HEPATOCEL? OR HEPATIC? OR HCC OR CIRRHO?) /TI AND S13 AND (S15+S10/TI)

S17 S16\*S12  
 S18 S17+S14  
 S19 S18/HUMAN+ (S18 NOT ANIMALS)  
 S20 S19/ENG  
 S21 S20 AND PY=>1982 AND UP=19830906 : 20111231

- **CQ11 What are the best tests for diagnosing typical HCC in high-risk HCC patients? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?)) (W) (CELL??+CELLULA?) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!  
 S2 S1/HUMAN+ (S1 NOT ANIMALS)  
 S3 S2/ENG  
 S4 S3 AND UP=20070701 : 20111231  
 S5 (DI+DIAGNOSIS!+RA+RI+US) /DF+ (DIAGNOS? OR DETECT? OR IDENTI?OR TEST? OR IMAG?) /TI  
 S6 SENSITIVIT?+SPECIFICIT?+ACCURAC?  
 S7 S4\*S5\*S6  
 S8 (USEFUL? OR EFFICAC? OR EFFECTIV?) /TI  
 S9 MT/DE  
 S10 S7\*S8\*S9  
 S11 S7\*S8+S7\*S9

- **CQ12 Is angiography necessary before HCC treatment? [MEDLINE]**
- **CQ13 Is CTAP/CTHA necessary before HCC treatment? [MEDLINE]**

S1 DT= (GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES+PRACTICE GUIDELINES) /DE+RECOMMENDATION?/TI+GUIDELINE? /TI+ CLINICAL PROTOCOLS /DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE /DE  
 S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) /TI+ (CLINICAL + TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+ (GOOD (1W) CLINICAL (1W) PRACTICE?) /TI  
 S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN= (COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+ EVID REP TECHNOL ASSESS?)  
 S4 DT=META-ANALYSIS+META-ANALYSIS/DE+ (META () ANALY?+METAANAL?) /TI  
 S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+ RANDOM ALLOCATION /DE + RANDOM? + DOUBLE-BLIND METHOD /DE + SINGLE-BLIND METHOD /DE+ (SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)

- S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/  
DE + SINGLE-BLIND METHOD/DE + CROSS-OVER STUDIES/DE + PLACEBO? + DT =  
COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL? (1W) (TRIAL?+STUD?)
- S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! /DE + (PHASE + CLINICAL + PILOT +  
ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI
- S8 COHORT STUDIES! + (RETROSPECTIV? + PROSPECTIV? + LONGITUDIN? + CROSS ( )  
SECTION?+COHORT?+FOLLOW ( ) UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+  
EPIDEMIOLOGIC STUDIES!
- S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+ (MULTICENT?+MULTI (W)  
CENT?) /TI
- S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE ( ) CONTROL/TI
- S11 S1 : S10
- S12 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+  
HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS)  
/TI\*LIVER NEOPLASMS!
- S13 S12/HUMAN+ (S12 NOT ANIMALS)
- S14 S13/ENG
- S15 S14 AND UP=20070701 : 20111231
- S16 PREEXAMINAT? + PRE ( 1W ) EXAMINAT? + PREDIAGNOS? + PRETREATMENT? +  
PRETHERAP?+PRE (1W) (DIAGNO?+TREATMENT?+THERAP?)
- S17 ANGIOGRAPHY! + ARTERIOGRAPH? + ANGIOGRAPH? + AORTOGRAP? +  
CINEANGIOGRAPH?+PHLEBOGRAPH?+PORTOGRAPH?+CTHA+CTAP+CT/AB+CT/  
TI+TOMOGRA?+MDCT+NMR+MRI+SPECT+PET
- S18 S15\*S16\*S17
- S19 S15\*S12/TI\*S17/TI
- S20 S18+S19
- **CQ14 What test methods are useful for diagnosing liver tumors in patients with decreased kidney and liver functions? [MEDLINE]**
- S1 (LIVER+HEPATIC?+HEPATO?+KIDNEY+RENAL+CK+CREATIN?) (3N) (FUNCTION?  
+ IMPAIR? + FAILUR? + INSUFFICIEN? + DETERIORA? + EXACERBAT? + DYSFUNCT? +  
HYPOFUNCT?+LESION?+DISORDER?+DAMAGE?+ABNORMAL?)
- S2 NEPHROPATH? OR CIRRHOSIS? OR NEPHRITIS?
- S3 JAUNDIC? OR HYPERBIL? OR (BIL OR BILI?) (3N) (RISE? OR RISING? OR ELEVAT? OR  
HIGH? OR INCREASES?)
- S4 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+  
HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS)  
/TI\*LIVER NEOPLASMS!
- S5 GD ( ) EOB ( ) DTPA+GADOXETIC? (3W) ENHANCE? (3W) (MRI OR MR)

S6 CONTRAST? (3W) (CT OR MR OR NMR OR MRI OR ULTRASON?)

S7 CTAP OR CTHA OR IODI? (3N) CONTRAST? OR GD OR GADOXETIC? OR DTPA OR EOB OR SONAZOID?

S8 CONTRAST? (3W) ENHANC? OR ENHANC? (3N) (CT OR MR OR NMR OR MRI OR ULTRASON?)

S9 (DI+DIAGNOSIS!+RA+RI+US) /DF

S10 (S1+S2+S3+S4) \*S5/TI

S11 (S1+S2+S3) \*S4\* (S5+S6+S7+S8) /TI

S12 (HEPATIC? OR HEPATO? OR LIVER? OR S1+S2+S3) /TI AND S11

S13 S12\*S9

S14 S13+S10

S15 S14/HUMAN+ (S14 NOT ANIMALS)

S16 S15 AND PY=>1982 AND UP=19830906 : 20111231

S17 S16/ENG

S18 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S19 S17 NOT S18

S20 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S21 S17\*S20

S22 S19+S21

- **CQ15 How should contrast media be used for the diagnostic imaging of HCC?**  
**[MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND UP=20070701 : 20111231

S5 DIAGNOSTIC IMAGING!+IMAGE PROCESSING, COMPUTER-ASSISTED!+TOMOGRAPH?+IMAG? + ANGIOGRAPHY! + ARTERIOGRAPH? + ANGIOGRAPH? + AORTOGRAP? + CINEANGIOGRAPH? + PHLEBOGRAPH? + PORTOGRAPH? + ULTRASONOGRAPHY! + ULTRASON?

S6 ECHOGRAPH? + ECHO? ? + SONOGR? + ULTRASOUND? + ULTRASONICS! + US /DF + NUCLEAR (1W) MEDICINE (2N) DIAGNOSIS?+NUCLEAR MEDICINE! \*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES, RADIOISOTOPE!+RADIONUCLIDE IMAGING!+SCINT?+MRI +SPECT+PET+CT+ (RA+RI) /DF

S7 CONTRAST MEDIA!+ (CONTRAST+RADIOPAQUE) (1N) (MEDIA?+DYE?+MATERIAL?+AGENT?)

S8 SENSITIVI? OR ACCURAC? OR SPECIFICI? OR ROC

S9 S4\* (S5+S6) \*S7

S10 S8\*S9

S11 (CONTRAST? OR IODINE? OR GD) /TI AND S9

S12 S10+S11

- **CQ16 Are head MRI, chest CT, bone scintigraphy, and FDG-PET necessary for determining the stage of HCC? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR /DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY=>1982 AND UP=19830906 : 20111231

S5 DIAGNOSTIC IMAGING!+IMAGE PROCESSING, COMPUTER-ASSISTED!+TOMOGRAPH?+IMAG? + ANGIOGRAPHY! + ARTERIOGRAPH? + ANGIOGRAPH? + AORTOGRAP? + CINEANGIOGRAPH? + PHLEBOGRAPH? + PORTOGRAPH? + ULTRASONOGRAPHY! + ULTRASON?

S6 ECHOGRAPH? + ECHO? ? + SONOGR? + ULTRASOUND? + ULTRASONICS! + US / DF + NUCLEAR (1W) MEDICINE (2N) DIAGNOSIS?+NUCLEAR MEDICINE! \*DIAGNOSIS!+DIAGNOSTIC TECHNIQUES, RADIOISOTOPE!+RADIONUCLIDE IMAGING!+SCINT?+MRI+SPECT+PET+CT+ (RA+RI) /DF

S7 STAGE? OR STAGING? OR METASTA? OR INFILTRA? OR INVASI? OR INVOLVE?

S8 S4\* (S5+S6) \*S7

S9 CT OR ULTRASONO? OR ULTRASONIC? OR NMR OR MRI OR IMAGE? OR IMAGING? OR DETECT? OR DIAGNOS?

S10 S8\* (S7/TI+S9/TI) \* (HEPATO? OR HEPATIC? OR LIVER?) /TI

S11 S10\* (S7/TI+DETECT?/TI+DIAGNO?/TI)

S12 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S13 S11 NOT S12

S14 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S15 S11\*S14

S16 S15+S13

- **CQ17 Does contrast-enhanced ultrasound improve the ability to diagnose HCC? [MEDLINE]**

S1 DT= (GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES+PRACTICE GUIDELINES) /DE+RECOMMENDATION?/TI+GUIDELINE? /TI+CLINICAL PROTOCOLS /DE+PATIENT CARE PLANNING!+EVIDENCE-BASED

MEDICINE/DE

- S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) /TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+ (GOOD (1W) CLINICAL (1W) PRACTICE?) /TI
- S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN= (COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+ EVID REP TECHNOL ASSESS?)
- S4 DT=META-ANALYSIS+META-ANALYSIS/DE+ (META () ANALY?+METAANAL?) /TI
- S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+ RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+ SINGLE-BLIND METHOD/DE+ (SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)
- S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+ SINGLE-BLIND METHOD/DE+ CROSS-OVER STUDIES/DE+ PLACEBO?+DT= COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL? (1W) (TRIAL?+STUD?)
- S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! /DE + (PHASE + CLINICAL + PILOT + ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI
- S8 COHORT STUDIES! + (RETROSPECTIV? + PROSPECTIV? + LONGITUDIN? + CROSS () SECTION?+COHORT?+FOLLOW () UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+ EPIDEMIOLOGIC STUDIES!
- S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+ (MULTICENT?+MULTI (W) CENT?) /TI
- S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE () CONTROL/TI
- S11 S1 : S10
- S12 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+ HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR? +TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!
- S13 S12/HUMAN+ (S12 NOT ANIMALS)
- S14 S13/ENG
- S15 S14\*UP=20070701 : 20111231
- S16 S11\*S15
- S17 ULTRASONOGRAPHY! + ULTRASON? + ECHOGRAPH? + ECHO? ? + SONOGR? + ULTRASOUND?+ULTRASONICS!+US/DF
- S18 CONTRAST MEDIA!+ (CONTRAST+RADIOPAQUE) (1N) (MEDIA?+DYE?+MATERIAL? +AGENT?) /TI
- S19 (DI OR DIAGNOSIS! OR RA OR RI OR US) /DF OR DIAGNOS?/TI
- S20 S16\*S17\*S18\*S19
- S21 S20\*S19/MAJ



S22 S21\*S17/MAJ

- **CQ18 Is contrast-enhanced ultrasound useful for determining the outcomes of local therapy and TACE? [MEDLINE]**

S1 DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)  
+(GUIDELINES+PRACTICE GUIDELINES)/DF+RECOMMENDATION?/TI+GUIDELINE?  
/TI+CLINICAL PROTOCOLS/DF+PATIENT CARE PLANNING!+EVIDENCE-BASED  
MEDICINE/DF

S2 (CLINICAL+CRITICAL+TREATMENT?+CARE) (2N) (PATH+PATHS+PATHWAY?+  
PROTOCOL?+PLANNING?+GOOD (2W) PRACTICE?) /TI

S3 (SYSTEMATIC+QUANTITATIVE+METHODOLOGIC+COLLABORATIVE+INTEGRATIVE)  
(1W) (REVIEW?+OVERVIEW?)/TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST  
REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP  
TECHNOLASSESS?)

S4 DT=META-ANALYSIS+META-ANALYSIS/DF+(META () ANALY?+METAANAL?) /  
TI

S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DF+  
RANDOM ALLOCATION/DF+RANDOM?+DOUBLE-BLIND METHOD/DF+SINGLE-  
BLIND METHOD/DF+(SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)

S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/  
DF+SINGLE-BLIND METHOD/DF+CROSS-OVER STUDIES/DF+PLACEBO?+DT=  
COMPARATIVE STUDY+COMPARATIVE STUDY/ID+CONTROL? (1W) (TRIAL?+STUD?)  
+PLACEBO?/TI

S7 DT=CLINICAL TRIAL?+CLINICAL TRIALS!+(TRIAL?+STUDY+STUDIES) /TI

S8 COHORT STUDIES!+COHORT?/TI

S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DF+(MULTICENT?+MULTI (W)  
CENT?) /TI

S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DF+CASE () (CONTROL+  
COMPARISON?+REFERENT?+REFERRENT?) /TI+RETROSPECTIVE?/TI

S11 S1 : S10

S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?  
HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?) /TI+(HEPATOMA? ?+HAEPATOMA? ?) /TI+(HCC+HCCS)  
/TI\*LIVER NEOPLASMS!

S13 S12/HUMAN+(S12 NOT ANIMALS)

S14 S13/ENG

S15 S14\*UP=20070701 : 20111231

S16 S11\*S15

S17 ULTRASONOGRAPHY! + ULTRASON? + ECHOGRAPH? + ECHO? ? + SONOGR? +  
ULTRASOUND?+ULTRASONICS!+US/DF

S18 (ANTITHROMBOTIC+ANTI (1W) THROMBOTIC) (1W) REGIMEN?+EMBOLIZE?+

- (EMBOL?+THROMBUS?) (1N) FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE  
+ ((TRANSCATHETER?+TRANSARTER?+TRANS) (W) (CATHETER?+ARTER??)) (3N)  
(EMBOLI?+CHEMOEMBOLI?)
- S19 (LOCAL+TOPICAL) (3N) (REMEDI?+THERAP?+TREATMENT?)
- S20 ( BENEFIT? + EFFECT? + EFFIC? + GAIN? + PERFORMANCE? + ACTION? ) ( 1N )  
(TREATMENT?+THERAP?+CURATIVE?)
- S21 S16\*S17\* (S18+S19) \*S20
- S22 S16\*S17\* (S18+S19)
- S23 S15\*S17\* (S18+S19) \*S20

### [Chapter 3] Surgery

- **CQ19 What assessment factors are appropriate for evaluating liver function prior to hepatectomy?**

What are the indications for surgery from the perspective of liver function? [MEDLINE]

- S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+  
HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?)/TI+ (HEPATOMA? ?+HAEPATOMA? ?)/TI+ (HCC+HCCS)  
/TI\*LIVER NEOPLASMS!
- S2 S1/HUMAN+ (S1 NOT ANIMALS)
- S3 S2/ENG
- S4 S3\*UP=20070701 : 20111231
- S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI
- S6 S4 NOT S5
- S7 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)  
/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE  
GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
- S8 S4\*S7
- S9 S6+S8
- S10 (HCC+LIVER+HEPAT?+NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)  
(3N) (RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR  
ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
- S11 HEPATECTOM?
- S12 S9 AND (S10 OR S11)
- S13 PREOPERAT?+PRESURGER?+ (BEFORE+PRE+PRIOR) (W) (OPERAT?+SURGER?)
- S14 PREDICT?/DE AND SURGERY/DE
- S15 S13+S14
- S16 S15 (3N) (ASSESSMENT? OR TEST? ?)
- S17 S15 AND (HEPAT? OR LIVER) (3N) (FUNCTION? OR STATUS?)
- S18 S12 AND (S16 OR S17)

- **CQ20 What is the standard surgical procedure for hepatectomy? [MEDLINE]**

- S1 CARCINOMA, HEPATOCELLULAR /DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!
- S2 S1/HUMAN+ (S1 NOT ANIMALS)
- S3 S2/ENG
- S4 S3 AND PY=>1982 AND UP=19830906 : 20111231
- S5 LIVER NEOPLASMS! (L) SU
- S6 HEPATECTOMY!
- S7 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?) /TI
- S8 (NEW? OR STANDARD? OR GOLDSTANDARD? OR APPROACH? OR METHOD? OR TECHNI?) /TI
- S9 HEPATECTOMY! (L) METHODS
- S10 (S5+S6) \*S7\*S8
- S11 (SEGMENT? OR SUBSEGMENT?) /TI\* (S5+S6) \*S8
- S12 S4\* (S9+S10+S11)

- **CQ21 What are the indications for hepatectomy in terms of tumor condition? [MEDLINE]**

- S1 CARCINOMA, HEPATOCELLULAR /DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!
- S2 S1/HUMAN+ (S1 NOT ANIMALS)
- S3 S2/ENG
- S4 S3 AND PY=>1982 AND UP=19830906 : 19900630
- S5 S3 AND PY=>1982 AND UP=19900630 : 19950630
- S6 S3 AND PY=>1982 AND UP=19950630 : 20000630
- S7 S3 AND PY=>1982 AND UP=20000630 : 20050630
- S8 S3 AND PY=>1982 AND UP=20050630 : 20111231
- S9 S4 : S8
- S10 DT=REVIEW? OR REVIEW? /TI OR DT=CASE REPORT? OR CASE () REPORT? /TI
- S11 S9 NOT S10
- S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? /TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
- S13 S9\*S12
- S14 S11+S13
- S15 HEPATECTOMY!

S16 LIVER NEOPLASMS (L) SU  
 S17 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTEATOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOVE?) /TI  
 S18 (INDICAT?+ADPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?) (3N) (PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)  
 S19 (EFFECTIV?+BENEFIT?) (3N) (PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)  
 S20 INDICAT? / TI + INDICAT? (3N) (SURGER?+SURGIC?+RESECT?+OPERAT?+HEPATECTOM?)  
 S21 S14\* (S15+S16+17) \* (S18+S19+S20)  
 S22 S21\*UP=20070701 : 20111231

• **CQ22 What are the prognostic factors after hepatectomy? [MEDLINE]**

S1 DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+(GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DE  
 S2 (CLINICAL+CRITICAL) (1W) (PATH+PATHS+PATHWAY?) /TI+(CLINICAL+TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+(GOOD (1W) CLINICAL (1W) PRACTICE?) /TI  
 S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)  
 S4 DT=META-ANALYSIS+META-ANALYSIS/DE+(META () ANALY?+METAANAL?) /TI  
 S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)  
 S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL? (1W) (TRIAL?+STUD?)  
 S7 DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI  
 S8 COHORT STUDIES!+(RETROSPECTIVE?+PROSPECTIV?+LONGITUDIN?+CROSS () SECTION?+COHORT?+FOLLOW () UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+EPIDEMIOLOGIC STUDIES!  
 S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI (W) CENT?) /TI  
 S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE () CONTROL/TI  
 S11 S1 : S10

S12 CARCINOMA, HEPATOCELLULAR / DF + (HEPATOCELL? + HAEPATOCELL? + (HEPATO? + HAEPATO? + LIVER?)) (W) (CELL?? + CELLULA?) (2N) (NEOPLASM? + CANCER? + TUMOR? + TUMOUR? + CARCINOM?) / TI + (HEPATOMA? ? + HAEPATOMA? ?) / TI + (HCC + HCCS) / TI \* LIVER NEOPLASMS!

S13 S12 / HUMAN + (S12 NOT ANIMALS)

S14 S13 / ENG

S15 S14 \* UP = 20070701 : 20111231

S16 S11 \* S15

S17 (HCC + LIVER + HEPAT?) (3N) (RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)

S18 HEPATECTOM?

S19 S16 AND (S17 OR S18)

S20 (PREDICT? OR PROGNOS?) (N) (FACTOR? OR VARIABL?)

S21 S19 AND S20

S22 S21 AND (CARCINOMA, HEPATOCELLULAR!) / MAJ

- **CQ23 Does the size of the resection margin affect prognosis? [MEDLINE]**

S1 DT = (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE? + (GUIDELINES + PRACTICE GUIDELINES) / DE + RECOMMENDATION? / TI + GUIDELINE? / TI + CLINICAL PROTOCOLS / DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE / DE

S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI

S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)

S4 DT = META-ANALYSIS + META-ANALYSIS / DE + (META () ANALY? + METAANAL?) / TI

S5 DT = RANDOMIZED CONTROLLED TRIAL + RANDOMIZED CONTROLLED TRIALS / DE + RANDOM ALLOCATION / DE + RANDOM? + DOUBLE-BLIND METHOD / DE + SINGLE-BLIND METHOD / DE + (SINGL? + DOUBLE? + TREBL? + TRIPL?) (W) (BLIND? + MASK?)

S6 DT = CONTROLLED CLINICAL TRIAL + CONTROLLED CLINICAL TRIALS! + PLACEBOS / DE + SINGLE-BLIND METHOD / DE + CROSS-OVER STUDIES / DE + PLACEBO? + DT = COMPARATIVE STUDY + COMPARATIVE STUDY / DE + CONTROL? (1W) (TRIAL? + STUD?)

S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! / DE + (PHASE + CLINICAL + PILOT + ESCALAT? + DOSE) (2W) (TRIAL? + STUDY + STUDIES) / TI

S8 COHORT STUDIES! + (RETROSPECTIV? + PROSPECTIV? + LONGITUDIN? + CROSS () SECTION? + COHORT? + FOLLOW () UP + FOLLOWUP) (1W) (STUDY + STUDIES) / TI +

EPIDEMIOLOGIC STUDIES!

- S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+ (MULTICENT?+MULTI (W) CENT?) /TI
- S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE () CONTROL/TI
- S11 S1 : S10
- S12 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+ HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR? +TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!
- S13 S12/HUMAN+ (S12 NOT ANIMALS)
- S14 S13/ENG
- S15 S14\*UP=20070701 : 20111231
- S16 S11\*S15
- S17 (HCC+LIVER+HEPAT?) (3N) (RESECT? OR EXCIS? OR EXTIRPAT? OR ABLAT? OR TRANSECT? OR REMOV? OR ISOLAT? OR SURG? OR OPERAT? OR LAPARO? OR ENUCLEAT?)
- S18 HEPATECTOM?
- S19 S16 AND (S17 OR S18)
- S20 SPECIM? OR SAMPL? OR TISSUE OR ORGANIZATION? OR MARGIN?
- S21 PROGNOSIS! + PROGNOS? + (TREATMENT? + LATE? + LONG (1W) TERM) (2N) (CONSEQUENCE?+OUTCOME?+RESULT?) +SURVIVAL (1W) RATE?+RECURRENCE? +RELAPSE?+REOCCURRENCE?
- S22 S19 AND S20 AND S21
- S23 S22 AND (CARCINOMA, HEPATOCELLULAR!) /MAJ
- **CQ24 Does anatomical hepatic resection affect prognosis? [MEDLINE]**
- S1 DT= (GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES+PRACTICE GUIDELINES) /DE+RECOMMENDATION?/TI+GUIDELINE? /TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DE
- S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) /TI+ (CLINICAL + TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+ (GOOD (1W) CLINICAL (1W) PRACTICE?) /TI
- S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN= (COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+ EVID REP TECHNOL ASSESS?)
- S4 DT=META-ANALYSIS+META-ANALYSIS/DE+ (META () ANALY?+METAANAL?) /TI
- S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+ RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+ SINGLE-

BLIND METHOD/DE+ (SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)

S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE + SINGLE-BLIND METHOD/DE + CROSS-OVER STUDIES/DE + PLACEBO? + DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL? (1W) (TRIAL?+STUD?)

S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! / DE + (PHASE + CLINICAL + PILOT + ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI

S8 COHORT STUDIES! + (RETROSPECTIV? + PROSPECTIV? + LONGITUDIN? + CROSS ( ) SECTION?+COHORT?+FOLLOW ( ) UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+ EPIDEMIOLOGIC STUDIES!

S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+ (MULTICENT?+MULTI (W) CENT?) /TI

S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE ( ) CONTROL/TI

S11 S1 : S10

S12 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S13 S12/HUMAN+ (S12 NOT ANIMALS)

S14 S13/ENG

S15 S14\*UP=20070701 : 20111231

S16 S11\*S15

S17 (ANATOMI?+SYSTEMIC?+SYSTEMATIC?) (4N) (RESECT?+HEPATECTOM?+SURGER?+SURGICA?+OPERATI?)

S18 PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S19 S16\*S17\*S18

- **CQ25 Is proactive, perioperative administration of blood products recommended? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S12 NOT ANIMALS)

S3 S2/ENG

S4 S3\*UP=20070701 : 20111231

S5 SU/DF+ SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER??+OPERAT?+HEPATECTOMY!+HEPATECTOM?+ (TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?) (3N) (RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)

S6 PERIOPERAT?+INTRAOPERAT?+ (PERI+INTRA+DURING?) (3N) (OP+SURGER??+)

- OPERAT?+HEPATECTOM?+RESECT?)
- S7 BLOOD TRANSFUSION! OR (BLOOD? OR ERYTHROCY? OR RED () CELL? ? OR PLASMA?)  
(3N) TRANSFUS? OR FROZEN? (3N) PLASMA?
- S8 BLOOD () (DERIVATIVE?+PREPARATION?+PRODUCT?+FORMUL?) + (HEMATOLOGIC?  
+HEMOPOIETIC?+HEMATOPOIETIC?) (2W) (DRUG? ?+AGENT? ?+FORMUL?)
- S9 S4\*S5\*S6\* (S7+S8)
- **CQ26 Does hepatic pedicle clamping and decreased central venous pressure decrease bleeding during liver resection? [MEDLINE]**
- S1 DT= (GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)  
+ (GUIDELINES+PRACTICE GUIDELINES) /DE+RECOMMENDATION?/TI+GUIDELINE?  
/TI+CLINICAL PROTOCOLS /DE+PATIENT CARE PLANNING!+EVIDENCE-BASED  
MEDICINE /DE
- S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) /TI+ (CLINICAL +  
TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+ (GOOD (1W) CLINICAL  
(1W) PRACTICE?) /TI
- S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR  
INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN= (COCHRANE  
DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+  
EVID REP TECHNOL ASSESS?)
- S4 DT=META-ANALYSIS+META-ANALYSIS /DE+ (META () ANALY?+METAANAL?) /  
TI
- S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS /DE+  
RANDOM ALLOCATION /DE+RANDOM?+DOUBLE-BLIND METHOD /DE+ SINGLE-  
BLIND METHOD /DE+ (SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)
- S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS /  
DE+ SINGLE-BLIND METHOD /DE+ CROSS-OVER STUDIES /DE+ PLACEBO?+DT=  
COMPARATIVE STUDY+COMPARATIVE STUDY /DE+CONTROL? (1W) (TRIAL?+STUD?)
- S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! /DE + (PHASE + CLINICAL + PILOT +  
ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI
- S8 COHORT STUDIES! + (RETROSPECTIV? + PROSPRCTIV? + LONGITUDIN? + CROSS ()  
SECTION?+COHORT?+FOLLOW () UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+  
EPIDEMIOLOGIC STUDIES!
- S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES /DE+ (MULTICENT?+MULTI (W)  
CENT?) /TI
- S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS /DE+CASE () CONTROL /TI
- S11 S1 : S10
- S12 S11 /HUMAN+ (S11 NOT ANIMALS)
- S13 S12 /ENG
- S14 S13 \*UP=20070701 : 20111231
- S15 SU /DF + SURGERY! + SURGICAL PROCEDURES, OPERATIVE! + SURGER???? + OPERAT? +



- HEPATECTOMY! + HEPATECTOM? + (TUMOR? + TUMOUR? + CANCER? + CARCINOM? + LIVER? + HEPAT?) (3N) (RESECT? + REMOV? + ENUCLEAT? + EXTIRPAT? + EXCIS? + AMPUTAT? + ABLAT?)
- S16 BLOOD LOSS, SURGICAL! + BLOOD ( ) LOSS? + (HEMORRHAGE? + BLEED? + HAEMORRHAG?) (3N) (OP+SURGIC?+SURGER???+OPERAT?+HEPATECTOM?+RESECT? +REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
- S17 S14\*S15\*S16
- S18 PEDICL? (1W) (CLAMP?+OCCLUS?) +IPO+HPC+PRINGL?
- S19 ((CENTRAL? (1W) VENOUS? (1W) PRESSUR?) +CVP) (3N) (REDUC?+LOW+DECREAS? +FALL??+DROP???)
- S20 S17\* (S18+S19)
- S21 PEDICL? (1W) (CLAMP?+OCCLUS?) +IPO+HPC+PRINGL?+PORTAL ( ) TRIAD ( ) CLAMP? +PTC
- S22 S17\* (S19+S21)
- **CQ27 Is abdominal drain placement necessary for hepatectomy? [MEDLINE]**
- S1 DT= (GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES+PRACTICE GUIDELINES) /DE+RECOMMENDATION? /TI+GUIDELINE? /TI+CLINICAL PROTOCOLS /DE+PATIENT CARE PLANNING! +EVIDENCE-BASED MEDICINE /DE
- S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) /TI+ (CLINICAL + TREATMENT?) (2N) PROTOCOL? /TI+CARE (1N) PLANNING? /TI+ (GOOD (1W) CLINICAL (1W) PRACTICE?) /TI
- S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN= (COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+ EVID REP TECHNOL ASSESS?)
- S4 DT=META-ANALYSIS+META-ANALYSIS /DE+ (META ( ) ANALY?+METAANAL?) /TI
- S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS /DE+ RANDOM ALLOCATION /DE+RANDOM? +DOUBLE-BLIND METHOD /DE+ SINGLE-BLIND METHOD /DE+ (SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)
- S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS /DE+ SINGLE-BLIND METHOD /DE+ CROSS-OVER STUDIES /DE+ PLACEBO? +DT= COMPARATIVE STUDY+COMPARATIVE STUDY /DE+CONTROL? (1W) (TRIAL?+STUD?)
- S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! /DE + (PHASE + CLINICAL + PILOT + WSCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI
- S8 COHORT STUDIES! + (RETROSPECTIV? + PROSPECTIV? + LONGITUDIN? + CROSS ( ) SECTION?+COHORT?+FOLLOW ( ) UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+ EPIDEMIOLOGIC STUDIES!
- S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES /DE+ (MULTICENT?+MULTI (W)

- CENT?) /TI
- S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE () CONTROL/TI
- S11 S1 : S10
- S12 S11/HUMAN+ (S12 NOT ANIMALS)
- S13 S12/ENG
- S14 S13 AND PY=>1982 AND UP=19830906 : 20111231
- S15 SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+ (TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?) (3N) (RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)
- S16 ABDOM? (2N) DRAIN?
- S17 S14\*S15\*S16
- **CQ28 Does neoadjuvant therapy improve prognosis after hepatectomy?**  
**[MEDLINE]**
- S1 DT=(GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+ (GUIDELINES+PRACTICE GUIDELINES)/DE+RECOMMENDATION?/TI+GUIDELINE?/TI+CLINICAL PROTOCOLS/DE+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DE
- S2 (CLINICAL+CRITICAL) (1W) (PATH+PATHS+PATHWAY?) /TI+ (CLINICAL+TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+(GOOD (1W) CLINICAL (1W) PRACTICE?) /TI
- S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN=(COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+EVID REP TECHNOL ASSESS?)
- S4 DT=META-ANALYSIS+META-ANALYSIS/DE+ (META () ANALY?+METAANAL?) /TI
- S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)
- S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL? (1W) (TRIAL?+STUD?)
- S7 DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+ (PHASE+CLINICAL+PILOT+ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI
- S8 COHORT STUDIES!+ (RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS () SECTION?+COHORT?+FOLLOW () UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+EPIDEMIOLOGIC STUDIES!
- S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+ (MULTICENT?+MULTI (W) CENT?) /TI

S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE () CONTROL/TI

S11 S1 : S10

S12 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S13 S12/HUMAN+ (S12 NOT ANIMALS)

S14 S13/ENG

S15 S14\*UP=20070701 : 20111231

S16 S11\*S15

S17 SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER???+OPERAT?+HEPATECTOMY!+HEPATECTOM?+POSTOPERAT?+POSTSURGER?+POSTHEPATECTOM?+ (TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?) (3N) (RESECT?+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)

S18 NEOADJUVANT?+NAC+NEO () ADJUVAN?

S19 (PREOPERAT?+ (BEFORE + PRE) (3N) (SURGER???+OPEARAT?+HEPATECTOM?+RESECT?)) (4N) (CHEMOEMB?+EMBOL?+CHEMOTHER?+THERAP?+TREAT?+ADMINIST?)

S20 (CHEMOTHERAPY!+ANTINEOPLASTIC AGENTS! OR DT/DE+CHEMOTHERAP?+DRUG THERAPY!) \* (PREOPERAT?+ (BEFORE + PRE) (3N) (SURGER???+OPEARAT?+HEPATECTOM?+RESECT?))

S21 S16\*S17\* (S18+S19+S20)

S22 PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S23 S21\*S22

- **CQ29 Does adjuvant therapy improve prognosis after hepatectomy?**  
**[MEDLINE]**

S1 DT= (GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)+ (GUIDELINES+PRACTICE GUIDELINES) /DE+RECOMMENDATION?/TI+GUIDELINE? /TI+CLINICAL PROTOCOLS /DE+PATIENT CARE PLANNING!+EVIDENCE-BASED MEDICINE/DE

S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) /TI+ (CLINICAL + TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+ (GOOD (1W) CLINICAL (1W) PRACTICE?) /TI

S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN= (COCHRANE DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+ EVID REP TECHNOL ASSESS?)

S4 DT=META-ANALYSIS+META-ANALYSIS/DE+ (META () ANALY?+METAANAL?) /TI

S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+  
RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-  
BLIND METHOD/DE+(SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)

S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/  
DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=  
COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL? (1W) (TRIAL?+STUD?)

S7 DT=CLINICAL TRIAL?+CLINICAL TRIALS!/DE+(PHASE+CLINICAL+PILOT+  
ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI

S8 COHORT STUDIES!+(RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS ( )  
SECTION?+COHORT?+FOLLOW ( ) UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+  
RETROSPECTIV STUDIES!

S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+(MULTICENT?+MULTI (W)  
CENT?) /TI

S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE ( ) CONTROL/TI

S11 S1 : S10

S12 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?  
HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?) /TI+(HEPATOMA? ?+HAEPATOMA? ?) /TI+(HCC+HCCS)  
/TI\*LIVER NEOPLASMS!

S13 S12/HUMAN+(S12 NOT ANIMALS)

S14 S13/ENG

S15 S14\*UP=20070701 : 20111231

S16 S11\*S15

S17 SU/DF+SURGERY!+SURGICAL PROCEDURES, OPERATIVE!+SURGER??+OPERAT?+  
HEPATECTOMY!+HEPATECTOM?+POSTOPERAT?+POSTSURGER?+POSTHEPATECTOM?  
+(TUMOR?+TUMOUR?+CANCER?+CARCINOM?+LIVER?+HEPAT?) (3N) (RESECT?  
+REMOV?+ENUCLEAT?+EXTIRPAT?+EXCIS?+AMPUTAT?+ABLAT?)

S18 CHEMOTHERAPY, ADJUVANT!+ADJUVANT? (3N) CHEMOTHER?

S19 (POSTOPERAT?+(AFTER+FOLLOW?) (3N) (SURGER??+OPEARAT?+HEPATECTOM?  
+RESECT?)) (4N) (CHEMOTHER?+THERAP?+TREAT?+ADMINIST?)

S20 (CHEMOTHERAPY!+ANTINEOPLASTIC AGENTS! OR DT/DE+CHEMOTHERAP?+DRUG  
THERAPY!) \* (POSTOPERAT?+(AFTER+FOLLOW?) (3N) (SURGER??+OPEARAT?+  
HEPATECTOM?+RESECT?))

S21 S16\*S17\* (S18+S19+S20)

S22 PROGNOSIS!+PROGNOS?+CONSEQUENCE?+OUTCOME?+SURVIVAL?+RECURRENCE?  
+RELAPSE?+REOCCURRENCE?

S23 S21\*S22

- **CQ30 Does pretransplantation tumor downstaging improve the prognosis of liver transplantation? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+(HEPATOCELL?+HAEPATOCELL?+(HEPATO?+

HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS)  
/TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND UP=20070701 : 20111231

S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S6 S4 NOT S5

S7 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)  
/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE  
GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8 S4\*S7

S9 S6+S8

S10 LIVER TRANSPLANTATION! OR LIVER! (L) TR OR TRANSPLAN?

S11 DOWN? () STAG? OR DOWNSTAG?

S12 S9\*S10\*S11

S13 PRE () TRANSPLAN? OR PRETRANSPLAN? OR TRANSPLAN? (3N) (BEFOR? OR FOLLOW?  
OR AFTER? OR WAIT?)

S14 BRIDGING? OR ABLAT? OR RFA

S15 (LOCAL?+LOCOREGION?+LOCO () REGION?+TOPICAL? OR BRIDG?) (3N) (THERAP?  
+TREAT?)

S16 TAE OR TACE OR (TRANSCATHETER? OR TRANSARTER?) (3N) (EMBOLI? OR  
CHEMOEMBOLI?)

S17 S13 (5N) (S14+S15+S16)

S18 S9\*S17

S19 S12+S18

- **CQ31 What are the criteria for liver transplantation in HCC patients?**

- **[MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?  
HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS)  
/TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND UP=20070701 : 20111231

S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S6 S4 NOT S5

S7 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)  
/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE  
GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S8 S4\*S7  
 S9 S6+S8  
 S10 LIVER TRANSPLANTATION! OR LIVER! (L) TR OR TRANSPLAN?  
 S11 LIVER TRANSPLANTATION! (L) UT OR TRANSPLANT? (3N) UTILIZ?  
 S12 (INDICAT? + ADAPT? + RECOMMEND? + SELECT? + CHOIC? + TARGET? + ELIGIBL? + CANDIDAT?+OFFER?) (4N) TRANSPLANT?  
 S13 CRITERI? (4N) S12  
 S14 S9\*S11  
 S15 S9\*S13  
 S16 S9\*S12  
 S17 S9\*TRANSPLAN?/TI\* (CRITERI?+PRIORIT?)  
 S18 S14+S15+S16+S17

#### [Chapter 4] Percutaneous Local Ablation

- **CQ32 Who are eligible candidates for percutaneous ablation? [PubMed]**
- **CQ33 How should the type of percutaneous ablation be selected? [PubMed]**
- **CQ34 Does a combination of TACE and percutaneous ablation improve prognosis? [PubMed]**
- **CQ35 Are fusion images obtained with contrast-enhanced ultrasound, computed tomography, and magnetic resonance imaging (MRI) useful guides for local therapy? [PubMed]**

#1 (“carcinoma, hepatocellular” [MH] OR “HCC” [tiab]) AND (“Ethanol Injection” [tiab] OR “Ablation” [tiab] OR “Ablative” [tiab] OR “Thermal Ablation” [tiab] OR “radiofrequency” [tiab] OR “RFA” [tiab] OR “RFTA” OR “PEI” [tiab] OR “PEIT” [tiab] OR “Ethanol/administration and dosage” [MH] OR “Injections, Intralesional” [MH] OR “microwave” [tiab]) AND 2007/7/1 : 2011/11/15 [dp] AND Eng [la] NOT “case reports” [pt]

#2 (“carcinoma, hepatocellular” [MH] OR “HCC” [tiab]) AND (“Ethanol Injection” [tiab] OR “Ablation” [tiab] OR “Ablative” [tiab] OR “Thermal Ablation” [tiab] OR “radiofrequency” [tiab] OR “RFA” [tiab] OR “RFTA” OR “PEI” [tiab] OR “PEIT” [tiab] OR “Ethanol/administration and dosage” [MH] OR “Injections, Intralesional” [MH] OR “microwave” [tiab]) AND 2007/7/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]

#3 #1 or #2

- **CQ36 What type of diagnostic imaging is useful for determining the outcome of local therapy? [PubMed]**

#1 (“carcinoma, hepatocellular” [MH] OR “HCC” [tiab]) AND (“Ethanol Injection” [tiab] OR “Ablation” [tiab] OR “Ablative” [tiab] OR “Thermal Ablation” [tiab] OR “radiofrequency” [tiab] OR “RFA” [tiab] OR “RFTA” OR “PEI” [tiab] OR “PEIT” [tiab] OR “Ethanol/administration and dosage” [MH] OR “Injections, Intralesional” [MH] OR “microwave” [tiab]) AND (“MRI” [tiab] OR “CT” [tiab] OR ultraso\* [tiab]) 1982/1/1 : 2011/11/15 [dp] AND Eng [la] NOT “case reports” [pt]

- #2 (“carcinoma, hepatocellular” [MH] OR “HCC” [tiab]) AND (“Ethanol Injection” [tiab] OR “Ablation” [tiab] OR “Ablative” [tiab] OR “Thermal Ablation” [tiab] OR “radiofrequency” [tiab] OR “RFA” [tiab] OR “RFTA” OR “PEI” [tiab] OR “PEIT” [tiab] OR “Ethanol/administration and dosage” [MH] OR “Injections, Intralesional” [MH] OR “microwave” [tiab]) AND (“MRI” [tiab] OR “CT” [tiab] OR ultraso\* [tiab]) 1982/1/1 : 2011/12/31 [dp] AND 2011/11/16 : 2012/3/30 [MHDA] AND Eng [la] NOT “case reports” [pt]
- #3 #1 or #2

## [Chapter 5] Transcatheter Arterial Chemoembolization (TACE)

### • CQ37 Who are eligible for TACE/TAE? [MEDLINE]

- S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+ (HEPATOMA? ?+HAEPATOMA? ?)/TI+ (HCC+HCCS)/TI\*LIVER NEOPLASMS!
- S2 S1/HUMAN+ (S1 NOT ANIMALS)
- S3 S2/ENG
- S4 S3 AND UP=20070701 : 20111231
- S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI
- S6 S4 NOT S5
- S7 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
- S8 S4\*S7
- S9 S6+S8
- S10 (ANTITHROMBOTIC + ANTI (1W) THROMBOTIC) (1W) REGIMEN? + EMBOLIZE? + (EMBOL?+THROMBUS?) (1N) FORM?+EMBOLIZATION, THERAPEUTIC!+TAE+TACE + ((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS) (W) (CATHETER?+ARTER???+ARTERIAL?)) (3N) (EMBOLI?+CHEMOEMBOLI?)
- S11 (INDICAT?+ADPT?+RECOMMEND?+SELECT?+CHOIC?+TARGET?) (3N) (PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
- S12 (EFFECTIV?+BENEFIT?) (3N) (PATIENT+PATIENTS+SUBJECT+SUBJECTS+CASE+CASES)
- S13 INDICAT?/TI+INDICAT? (3N) (ETHANOL?+RFA+PEI+PMCT+ABLAT?)
- S14 S9\*S10\* (S11 : S13)

### • CQ38 What type of embolic material or anticancer agent should be used in TACE/TAE? [MEDLINE]

- S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+ (HEPATOMA? ?+HAEPATOMA? ?)/TI+ (HCC+HCCS)/TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)  
 S3 S2/ENG  
 S4 S3 AND UP=20070701 : 20111231  
 S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI  
 S6 S4 NOT S5  
 S7 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)  
 /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE  
 GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!  
 S8 S4\*S7  
 S9 S6+S8  
 S10 (ANTITHROMBOTIC+ANTI (1W) THROMBOTIC) (1W) REGIMEN?+TAE+TACE  
 S11 ((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS) (W) (CATHETER?  
 +ARTER??+ARTERIAL?)) (3N) (EMBOLI?+CHEMOEMBOLI?+INFUS? OR INJECT? OR  
 CHEMOINFU?)  
 S12 CHEMOEMBOLIZATION, THERAPEUTIC!  
 S13 S9\* (S10+S11+S12)  
 S14 AD/DE+TU/DE  
 S15 ANTINEOPLASTIC AGENTS! (L) (TU+AD)  
 S16 S13\* (S14+S15)  
 S17 TRANSCATHETER? OR TRANSARTER? OR TRANS OR EMBOLI? OR CHEMOEMBOLI?  
 S18 SUSPENS? OR MICROSPHE? OR OIL? ? OR CARRIER? OR BEAD? ? OR MATERIAL? OR  
 AGENT? ? OR DRUG? ? OR COMPOUND? ? OR EMULS?  
 S19 S9\*S17/TI\*S18/TI  
 S20 S17/TI\*S16  
 S21 S20\*S18/DE  
 S22 S19+S21

• **CQ39 How should repeat TACE/TAE be scheduled? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?  
 HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
 +TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS)  
 /TI\*LIVER NEOPLASMS!  
 S2 S1/HUMAN+ (S1 NOT ANIMALS)  
 S3 S2/ENG  
 S4 S3 AND UP=20070701 : 20111231  
 S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI  
 S6 S4 NOT S5  
 S7 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)  
 /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE  
 GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!  
 S8 S4\*S7



S9 S6+S8

S10 (ANTITHROMBOTIC+ANTI (1W) THROMBOTIC) (1W) REGIMEN?+TAE+TACE

S11 ((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS) (W) (CATHETER?+ARTER??+ARTERIAL?)) (3N) (EMBOLI?+CHEMOEMBOLI?+INFUS? OR INJECT? OR CHEMOINFU?)

S12 CHEMOEMBOLIZATION, THERAPEUTIC! OR CHEMOTHERAPY, ADJUVANT!

S13 S9\* (S10+S11+S12)

S14 RETRI?+RE () TRI??+RETRY?+RE () TRY?+TRY () AGAIN?+REPERFORM?+RE () PERFORM?

S15 ANOTHER? + REPEAT? + ADDITION? + SUPPLEMENT? + TWICE? + TWO () TIMES? + RETREATMENT?+RE () TREATMENT?+AGAIN?

S16 SECOND? OR 2ND

S17 RETHERAP? OR REAPPROACH? OR RE () (THERAP? OR APPROACH?)

S18 REEMBOLI? OR RECHEMOEMBOLI? OR RETRANSCATHE? OR RETRANSARTER?

S19 RETACE? OR RETAE OR RETRANSANTITHROMBO?

S20 RE () (TACE OR TAE OR ANTITHROMBO? OR ANTI () THROMBO?) OR REANTITHROMBO?

S21 S13\* (S14+S15+S16+S17+S18) /TI

S22 TIME? OR TIMING? OR PERIOD? OR INTERVAL? OR OCCASION? OR POINT?

S23 S13\*S18

S24 S13\* (S14+S15+S16+S17+S18)

S25 S24\*S22

S26 (S14+S15+S16+S17) (4N) (TACE OR TAE OR TRANSCATHE? OR TRANSARTE? OR EMBOLI? OR CHEMOEMBOLI? OR TREAT? OR THERAP?)

S27 S26\*S24

S28 TRANSCATHETER? OR TRANSARTER? OR TRANS OR EMBOLI? OR CHEMOEMBOLI? OR TAE OR TACE

S29 (S27+S25) \*S28/TI

S30 S29+S21

- **CQ40 What types of diagnostic imaging techniques are useful for determining the treatment outcome of TACE? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY=>1982 AND UP=19830906 : 19900630

S5 S3 AND PY=>1982 AND UP=19900630 : 19950630

S6 S3 AND PY=>1982 AND UP=19950630 : 20000630

S7 S3 AND PY=>1982 AND UP=20000630 : 20050630

S8 S3 AND PY=>1982 AND UP=20050630 : 20111231

S9 S4 : S8

S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S11 S9 NOT S10

S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)  
/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE  
GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9\*S12

S14 S11+S13

S15 (ANTITHROMBOTIC+ANTI (1W) THROMBOTIC) (1W) REGIMEN?+TAE+TACE

S16 ((TRANSCATHETER?+TRANSARTER?+TRANSARTERIAL?+TRANS) (W) (CATHETER?  
+ARTER??+ARTERIAL?)) (3N) (EMBOLI?+CHEMOEMBOLI?+INFUS? OR INJECT? OR  
CHEMOINFU?)

S17 CHEMOEMBOLIZATION, THERAPEUTIC!

S18 S14\* (S15+S16+S17)

S19 (S15 OR CHEMOEMBOLI? OR CHEMOINFU? OR LOCOREGIONAL? () THERAP?) /TI

S20 RA/DF OR US/DF OR RI/DF OR DIAGNOSTIC IMAGING! OR LIVER NEOPLASMS! (L) PA

S21 ((TUMOR OR TUMOUR) () RESPONSE? OR INDICATOR? OR VISUALIZ? OR ASSESS? OR  
EVALUAT? OR THERAPEUTIC () EFFECT? OR IMAGING? OR FEATURE? OR FINDING? OR CT  
OR MR OR MRI) /TI

S22 (USEFUL? OR EFFECTIVE? OR EFFICAC? OR BENEFIT?) /TI

S23 S18\*S19\*S20

S24 S23\* (S21+S22)

## [Chapter 6] Chemotherapy

- **CQ41 Who are eligible candidates for systemic chemotherapy? [MEDLINE]**

S1 DT= (GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)  
+ (GUIDELINES+PRACTICE GUIDELINES) /DE+RECOMMENDATION?/TI+GUIDELINE?  
/TI+CLINICAL PROTOCOLS /DE +PATIENT CARE PLANNING! +EVIDENCE-BASED  
MEDICINE /DE

S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) /TI + (CLINICAL +  
TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+ (GOOD (1W) CLINICAL  
(1W) PRACTICE?) /TI

S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR  
INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN= (COCHRANE  
DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+  
EVID REP TECHNOL ASSESS?)

S4 DT=META-ANALYSIS+META-ANALYSIS /DE+ (META () ANALY?+METAANAL?) /  
TI

S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS /DE+

RANDOM ALLOCATION / DE + RANDOM? + DOUBLE-BLIND METHOD / DE + SINGLE-BLIND METHOD / DE + (SINGL? + DOUBLE? + TREBL? + TRIPL?) (W) (BLIND? + MASK?)  
 S6 DT=CONTROLLED CLINICAL TRIAL + CONTROLLED CLINICAL TRIALS! + PLACEBOS / DE + SINGLE-BLIND METHOD / DE + CROSS-OVER STUDIES / DE + PLACEBO? + DT = COMPARATIVE STUDY + COMPARATIVE STUDY / DE + CONTROL? (1W) (TRIAL? + STUD?)  
 S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! / DE + (PHASE + CLINICAL + PILOT + ESCALAT? + DOSE) (2W) (TRIAL? + STUDY + STUDIES) / TI  
 S8 COHORT STUDIES! + (RETROSPECTIV? + PROSPECTIV? + LONGITUDIN? + CROSS ( ) SECTION? + COHORT? + FOLLOW ( ) UP + FOLLOWUP) (1W) (STUDY + STUDIES) / TI + EPIDEMIOLOGIC STUDIES!  
 S9 DT = MULTICENTER STUDY + MULTICENTER STUDIES / DE + (MULTICENT? + MULTI (W) CENT?) / TI  
 S10 CASE-CONTROL STUDIES! + MATCHED-PAIR ANALYSIS / DE + CASE ( ) CONTROL / TI  
 S11 S1 : S10  
 S12 CARCINOMA, HEPATOCELLULAR / DF + (HEPATOCELL? + HAEPATOCELL? + (HEPATO? + HAEPATO? + LIVER?) (W) (CELL?? + CELLULA?)) (2N) (NEOPLASM? + CANCER? + TUMOR? + TUMOUR? + CARCINOM?) / TI + (HEPATOMA? ? + HAEPATOMA? ?) / TI + (HCC + HCCS) / TI \* LIVER NEOPLASMS!  
 S13 S12 / HUMAN + (S12 NOT ANIMALS)  
 S14 S13 / ENG  
 S15 S14 AND UP = 20070701 : 20111231  
 S16 S11 \* S15  
 S17 DRUG THERAPY! + DT / DF + RADIOCHEM? + CHEMORADIO? + CHEMOTHERAP? + ANTINEOPLASTIC AGENTS! (L) (TU + AD) + CYCLOPHOSPHAMIDE? + FLUOROURACIL? + 5 (1W) FU + 5FU + TEGAFUR? + UFT + CYTARABINE? + DOXORUBICIN? + ADRIAMYCIN? + EPIRUBICIN? + MITOXANTRONE? + MITOMYCIN? + CISPLATIN? + SORAFENIB?  
 S18 S16 \* S17  
 S19 S17 / TI AND S18  
 S20 DRUG THERAPY! + DT / DF + ANTINEOPLASTIC AGENTS! (L) (TU + AD)  
 S21 S18 \* S20  
 S22 S20 / MAJ AND S21  
 S23 S22 + S19  
 S24 DT = REVIEW? OR REVIEW? / TI OR DT = CASE REPORT? OR CASE ( ) REPORT? / TI  
 S25 DT = META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) / TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!  
 S26 S23 NOT S24  
 S27 S23 \* S25  
 S28 S26 + S27

- **CQ42 Does hepatic arterial infusion chemotherapy improve prognosis?**

**[MEDLINE]**

- S1 CARCINOMA, HEPATOCELLULAR / DF + (HEPATOCELL? + HAEPATOCELL? + (HEPATO? + HAEPATO? + LIVER?) (W) (CELL?? + CELLULA?)) (2N) (NEOPLASM? + CANCER? + TUMOR? + TUMOUR? + CARCINOM?) / TI + (HEPATOMA? ? + HAEPATOMA? ?) / TI + (HCC + HCCS) / TI \* LIVER NEOPLASMS!
- S2 S1 / HUMAN + (S1 NOT ANIMALS)
- S3 S2 / ENG
- S4 S3 AND UP=20070701 : 20111231
- S5 DT=REVIEW? OR REVIEW? / TI OR DT=CASE REPORT? OR CASE ( ) REPORT? / TI
- S6 DT=META-ANALYSIS or (META (1W) ANALY? OR METAANAL?) / TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
- S7 S4 NOT S5
- S8 S4 \* S6
- S9 S7 + S8
- S10 DRUG THERAPY! + DT / DF + RADIOCHEM? + CHEMORADIO? + CHEMOTHERAP? + ANTINEOPLASTIC AGENTS! (L) (TU + AD) + CYCLOPHOSPHAMIDE? + FLUOROURACIL? + 5 (1W) FU + 5FU + TEGAFUR? + UFT + CYTARABINE? + DOXORUBICIN? + ADRIAMYCIN? + EPIRUBICIN? + MITOXANTRONE? + MITOMYCIN? + CISPLATIN? + SORAFENIB?
- S11 S9 \* S10
- S12 HAI + (INTRAARTER? + ARTER?) (3N) (ADMINISTR? + DOSE? + DOSING? + INFUS? + INJECT?)
- S13 (INTRAARTER? OR ARTER?) (3N) (THERAP? OR CHEMOTHERAP? OR TREAT?)
- S14 PROGNOSIS! + PROGNOS? + OUTCOME? + SURVIV? + RECURRENCE? + RELAPSE? + REOCCURRENCE?
- S15 S11 \* (S12 + 13) \* S14

- **CQ43 Which chemotherapy regimens (drug regimens) are effective?**

**[MEDLINE]**

- S1 DT= (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES + PRACTICE GUIDELINES) / DE + RECOMMENDATION? / TI + GUIDELINE? / TI + CLINICAL PROTOCOLS / DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE / DE
- S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI
- S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)

S4 DT=META-ANALYSIS+META-ANALYSIS/DE+ (META () ANALY?+METAANAL?) /TI

S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS/DE+RANDOM ALLOCATION/DE+RANDOM?+DOUBLE-BLIND METHOD/DE+SINGLE-BLIND METHOD/DE+ (SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)

S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS/DE+SINGLE-BLIND METHOD/DE+CROSS-OVER STUDIES/DE+PLACEBO?+DT=COMPARATIVE STUDY+COMPARATIVE STUDY/DE+CONTROL? (1W) (TRIAL?+STUD?)

S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! /DE + (PHASE + CLINICAL + PILOT + ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI

S8 COHORT STUDIES! + (RETROSPECTIV? + PROSPECTIV? + LONGITUDIN? + CROSS () SECTION?+COHORT?+FOLLOW () UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+EPIDEMIOLOGIC STUDIES!

S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES/DE+ (MULTICENT?+MULTI (W) CENT?) /TI

S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE () CONTROL/TI

S11 S1 : S10

S12 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S13 S12/HUMAN+ (S12 NOT ANIMALS)

S14 S13/ENG

S15 S14 AND UP=20070701 : 20111231

S16 S11 \* S15

S17 DRUG THERAPY! + DT / DF + RADIOCHEM? + CHEMORADIO? + CHEMOTHERAP? + ANTINEOPLASTIC AGENTS! (L) (TU+AD) +CYCLOPHOSPHAMIDE?+FLUOROURACIL? +5 (1W) FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN?+EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?

S18 DRUG THERAPY!+DT/DF+ANTINEOPLASTIC AGENTS! (L) (TU+AD)

S19 S16\* (S17/TI+S18/MAJ)

S20 S19\*S12/TI

S21 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S22 DT=META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S23 S20 NOT S21

S24 S20 \* S22

S25 S23 + S24

- **CQ44 Is hormone therapy effective? [MEDLINE]**

- S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!
- S2 S1/HUMAN+ (S1 NOT ANIMALS)
- S3 S2/ENG
- S4 S3 AND UP=20070701 : 20111231
- S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI
- S6 DT=META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
- S7 S4 NOT S5
- S8 S4\*S6
- S9 S7+S8
- S10 GONADOTROPIN-RELEASING HORMONE!+ (LUTEINI?+GONADOTROPIN?) (3N) RELEAS? (2N) HORMON? (2N) (AGONIST?+ANALOG?) +LH (1W) RH+LHRH+GONADORELIN? + (GNRH+LHRH+ (GN+LH) (1W) RH) (W) (AGONIST?+ANALOGUE?) +BUSERELIN? +GOSERELIN?+LEUPROLI?+NAFARELIN?+TRIPTORELIN?
- S11 AROMATASE INHIBITORS! + AROMATAS? (2N) INHIBIT? + AMINOGLUTETHIMID? + TESTOLACTON?+FADROZOL?+ANASTROZOL?+LETROZOL?+EXEMESTAN?
- S12 TAMOXIFEN?+ADOPAN+EMALOOK+SOSHIGEN+TASUOMIN+NORXIFEN+NOLVADEX+PANLEEF+PHENOLURN+RESPOL+ICI (1W) 46474+ICI46474+ICI (1W) 47699+ICI47699+ZITAZONIUM
- S13 S10 : S12
- S14 S S9\*S13

- **CQ45 What are the predictive and prognostic factors for the treatment outcomes of chemotherapy (drug therapy)? [MEDLINE]**

- S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!
- S2 S1/HUMAN+ (S1 NOT ANIMALS)
- S3 S2/ENG
- S4 S3 AND UP=20070701 : 20111231
- S5 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI
- S6 DT=META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
- S7 S4 NOT S5

S8 S4\*S6

S9 S7+S8

S10 (PROGNOS?+PREDICT?) (1W) (FACTOR?+VARIABLE?+INDEX+INDIC?) +PREDICTOR?

S11 S9\*S10

S12 (BENEFIT? + EFFECT? + EFFIC? + GAIN? + PERFORMANCE? + ACTION? + RESPON? + OUTCOM?) (3N) (CHEMOTHER? + CHEMORADIOOTHER? + TREATMENT? + THERAP? + CURATIVE?)

S13 S11\*S12

S14 DRUG THERAPY! + DT / DF + RADIOCHEM? + CHEMORADIO? + CHEMOTHERAP? + ANTINEOPLASTIC AGENTS! (L) (TU+AD) +CYCLOPHOSPHAMIDE?+FLUOROURACIL? +5 (1W) FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN? +EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?

S15 S13\*S14

- **CQ46 How should the treatment outcome of chemotherapy be determined?**  
**[MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR / DF + (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+ HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR? +TUMOUR?+CARCINOM?) / TI + (HEPATOMA? ?+HAEPATOMA? ?) / TI + (HCC+HCCS) / TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY=>1982 AND UP=19830906 : 19900630

S5 S3 AND PY=>1982 AND UP=19900630 : 19950630

S6 S3 AND PY=>1982 AND UP=19950630 : 20000630

S7 S3 AND PY=>1982 AND UP=20000630 : 20050630

S8 S3 AND PY=>1982 AND UP=20050630 : 20111231

S9 S4 : S8

S10 DT=REVIEW? OR REVIEW? / TI OR DT=CASE REPORT? OR CASE () REPORT? / TI

S11 DT=META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) / TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S12 S9 NOT S10

S13 S9\*S11

S14 S12+S13

S15 DRUG THERAPY! + DT / DF + RADIOCHEM? + CHEMORADIO? + CHEMOTHERAP? + ANTINEOPLASTIC AGENTS! (L) (TU+AD) +CYCLOPHOSPHAMIDE?+FLUOROURACIL? +5 (1W) FU+5FU+TEGAFUR?+UFT+CYTARABINE?+DOXORUBICIN?+ADRIAMYCIN? +EPIRUBICIN?+MITOXANTRONE?+MITOMYCIN?+CISPLATIN?+SORAFENIB?

S16 RESPON? (2N) (CRITERIA?+EVALUAT?)

S17 S14\*S15\*S16

- **CQ47 What are the adverse effects of chemotherapy, and how should they be treated? [MEDLINE]**

- S1 CARCINOMA, HEPATOCELLULAR / DF + (HEPATOCELL? + HAEPATOCELL? + (HEPATO? + HAEPATO? + LIVER?)) (W) (CELL?? + CELLULA?) (2N) (NEOPLASM? + CANCER? + TUMOR? + TUMOUR? + CARCINOM?) / TI + (HEPATOMA? ? + HAEPATOMA? ?) / TI + (HCC + HCCS) / TI \* LIVER NEOPLASMS!
- S2 S1 / HUMAN + (S1 NOT ANIMALS)
- S3 S2 / ENG
- S4 S3 AND PY = > 1982 AND UP = 19830906 : 19900630
- S5 S3 AND PY = > 1982 AND UP = 19900630 : 19950630
- S6 S3 AND PY = > 1982 AND UP = 19950630 : 20000630
- S7 S3 AND PY = > 1982 AND UP = 20000630 : 20050630
- S8 S3 AND PY = > 1982 AND UP = 20050630 : 20111231
- S9 S4 : S8
- S10 DT = (GUIDELINE + PRACTICE GUIDELINE + CONSENSUS DEVELOPMENT CONFERENCE?) + (GUIDELINES + PRACTICE GUIDELINES) / DE + RECOMMENDATION? / TI + GUIDELINE? / TI + CLINICAL PROTOCOLS / DE + PATIENT CARE PLANNING! + EVIDENCE-BASED MEDICINE / DE
- S11 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) / TI + (CLINICAL + TREATMENT?) (2N) PROTOCOL? / TI + CARE (1N) PLANNING? / TI + (GOOD (1W) CLINICAL (1W) PRACTICE?) / TI
- S12 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) / TI + PEER REVIEW! + JN = (COCHRANE DATABASE SYST REV + ACP JOURNAL CLUB + ACP J CLUB + HEALTH TECHNOL ASSESS + EVID REP TECHNOL ASSESS?)
- S13 DT = META-ANALYSIS + META-ANALYSIS / DE + (META () ANALY? + METAANAL?) / TI
- S14 DT = REVIEW? OR REVIEW? / TI OR DT = CASE REPORT? OR CASE () REPORT? / TI
- S15 DT = META-ANALYSIS OR (META (1W) ANALY? OR METAANAL?) / TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!
- S16 S9 NOT S14
- S17 S9 \* S15
- S18 S16 + S17
- S19 DRUG THERAPY! + DT / DF + RADIOCHEM? + CHEMORADIO? + CHEMOTHERAP? + ANTINEOPLASTIC AGENTS! (L) (TU + AD) + CYCLOPHOSPHAMIDE? + FLUOROURACIL? + 5 (1W) FU + 5FU + TEGAFUR? + UFT + CYTARABINE? + DOXORUBICIN? + ADRIAMYCIN? + EPIRUBICIN? + MITOXANTRONE? + MITOMYCIN? + CISPLATIN? + SORAFENIB?
- S20 ANTINEOPLASTIC AGENTS! (L) (AE + PO + CT + TO)
- S21 (ADVERS? + SAFETY + TOXIC?) / TI



- S22 (ADVERS?+SAFETY+TOXIC?) (2N) (MANAG?+PROPHYLAX?+PREVEN?)  
 S23 S18\*S19  
 S24 S23\*S21+S23\*S22\*S20+S20\* (S10 : S13) \*S23

## [Chapter 7] Radiation Therapy

- **CQ48 Is 3D conformal radiation therapy useful for HCC? [MEDLINE]**

- S1 DT= (GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)  
 + (GUIDELINES+PRACTICE GUIDELINES) /DE+RECOMMENDATION?/TI+GUIDELINE?  
 /TI+CLINICAL PROTOCOLS /DE+PATIENT CARE PLANNING!+EVIDENCE-BASED  
 MEDICINE /DE
- S2 (CLINICAL+CRITICAL) (1W) (PATH+PATHS+PATHWAY?) /TI+ (CLINICAL+  
 TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+ (GOOD (1W) CLINICAL  
 (1W) PRACTICE?) /TI
- S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR  
 INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN= (COCHRANE  
 DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+  
 EVID REP TECHNOL ASSESS?)
- S4 DT=META-ANALYSIS+META-ANALYSIS /DE+ (META () ANALY?+METAANAL?) /  
 TI
- S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS /DE+  
 RANDOM ALLOCATION /DE+RANDOM?+DOUBLE-BLIND METHOD /DE+ SINGLE-  
 BLIND METHOD /DE+ (SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)
- S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS /  
 DE+ SINGLE-BLIND METHOD /DE+ CROSS-OVER STUDIES /DE+ PLACEBO?+DT=  
 COMPARATIVE STUDY+COMPARATIVE STUDY /DE+CONTROL? (1W) (TRIAL?+STUD?)
- S7 DT=CLINICAL TRIAL?+CLINICAL TRIALS! /DE+ (PHASE+CLINICAL+PILOT+  
 ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI
- S8 COHORT STUDIES!+ (RETROSPECTIV?+PROSPECTIV?+LONGITUDIN?+CROSS ()  
 SECTION?+COHORT?+FOLLOW () UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+  
 EPIDEMIOLOGIC STUDIES!
- S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES /DE+ (MULTICENT?+MULTI (W)  
 CENT?) /TI
- S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS /DE+CASE () CONTROL /TI
- S11 S1 : S10
- S12 CARCINOMA, HEPATOCELLULAR!+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO+  
 HAEPATO)) (W) (CELL??+CELLULA?) (2N) (NEOPLASM?+CANCER?+TUMOR?+  
 TUMOUR?+CARCINOM?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!
- S13 S11\*S12
- S14 S13/HUMAN OR (S13 NOT ANIMALS)
- S15 S14/ENG

S16 S15 AND UP=20070701 : 20111231

S17 RADIOTHERAPY! + RT / DF + RADIOCHEM? + CHEMORADIO? + IRRADIAT? +  
RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?

S18 S16\*S17

S19 PROGNOSIS!+PROGNOS?+OUTCOME?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S20 EFFECACY OR SURVIVAL? OR RESPONSE () (RATE OR RATES) OR LOCAL () CONTROL?  
OR SAFETY OR ADVERS? (1W) (EFFECT? OR EVENT OR EVENTS) OR TOXICITY OR  
FEASIBILITY

S21 S19+S20

S22 S18\*S21

• **CQ49 Is stereotactic body radiation therapy useful for HCC? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR / DF + (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+  
HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?) / TI + (HEPATOMA? ?+HAEPATOMA? ?) / TI + (HCC+HCCS)  
/ TI \* LIVER NEOPLASMS!

S2 STEREOTACTIC (3N) (RADIOTHERAP? OR RADIOSURG? OR RADIATION? OR IRRADIAT?)

S3 RADIOTHERAPY! + RT / DF + RADIOCHEM? + CHEMORADIO? + IRRADIAT? +  
RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?

S4 SBRT OR SBT OR SRT OR STEREOTACTIC OR PINPOINT?

S5 DT=REVIEW?

S6 S1 NOT S5

S7 S6 / HUMAN + (S6 NOT ANIMALS)

S8 S7 / ENG

S9 S8 AND PY => 1982 AND UP=19830906 : 19900630

S10 S8 AND PY => 1982 AND UP=19900630 : 19950630

S11 S8 AND PY => 1982 AND UP=19950630 : 20000630

S12 S8 AND PY => 1982 AND UP=20000630 : 20050630

S13 S8 AND PY => 1982 AND UP=20050630 : 20111231

S14 S9 : S13

S15 S14\*S2

S16 S14\*S3\*S4

S17 S15+S16

• **CQ50 Is particle radiation therapy [proton therapy, heavy particle (carbon ion) radiation therapy] useful against HCC? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR / DF + (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+  
HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?) / TI + (HEPATOMA? ?+HAEPATOMA? ?) / TI + (HCC+HCCS)  
/ TI \* LIVER NEOPLASMS!

S2 (HEAVY OR CARBON? OR PROTON? OR PARTICL?) (2N) (THERAP? OR ION OR IONS OR  
BEAM OR BEAMS OR IRRADIAT? OR RADIOISOTOP?)

- S3 RADIO THERAPY! + RT / DF + RADIOCHEM? + CHEMORADIO? + IRRADIAT? +  
RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?
- S4 DT=REVIEW?
- S5 S1 NOT S4
- S6 S5/HUMAN+ (S5 NOT ANIMALS)
- S7 S6/ENG
- S8 S7 AND PY=>1982 AND UP=19830906 : 19900630
- S9 S7 AND PY=>1982 AND UP=19900630 : 19950630
- S10 S7 AND PY=>1982 AND UP=19950630 : 20000630
- S11 S7 AND PY=>1982 AND UP=20000630 : 20050630
- S12 S7 AND PY=>1982 AND UP=20050630 : 20111231
- S13 S8 : S12
- S14 S13\*S2\*S3

- **CQ51 Is radiation therapy indicated for distant metastases from hepatocellular carcinoma? [MEDLINE]**

- S1 DT= (GUIDELINE+PRACTICE GUIDELINE+CONSENSUS DEVELOPMENT CONFERENCE?)  
+ (GUIDELINES+PRACTICE GUIDELINES) /DE+RECOMMENDATION?/TI+GUIDELINE?  
/TI+CLINICAL PROTOCOLS /DE + PATIENT CARE PLANNING! + EVIDENCE-BASED  
MEDICINE /DE
- S2 (CLINICAL + CRITICAL) (1W) (PATH + PATHS + PATHWAY?) /TI + (CLINICAL +  
TREATMENT?) (2N) PROTOCOL?/TI+CARE (1N) PLANNING?/TI+ (GOOD (1W) CLINICAL  
(1W) PRACTICE?) /TI
- S3 (SYSTEMATIC OR QUANTITATIVE OR METHODOLOGIC OR COLLABORATIVE OR  
INTEGRATIVE) (1W) (REVIEW? OR OVERVIEW?) /TI+PEER REVIEW!+JN= (COCHRANE  
DATABASE SYST REV+ACP JOURNAL CLUB+ACP J CLUB+HEALTH TECHNOL ASSESS+  
EVID REP TECHNOL ASSESS?)
- S4 DT=META-ANALYSIS+META-ANALYSIS /DE+ (META () ANALY?+METAANAL?) /  
TI
- S5 DT=RANDOMIZED CONTROLLED TRIAL+RANDOMIZED CONTROLLED TRIALS /DE+  
RANDOM ALLOCATION /DE + RANDOM? + DOUBLE-BLIND METHOD /DE + SINGLE-  
BLIND METHOD /DE+ (SINGL?+DOUBLE?+TREBL?+TRIPL?) (W) (BLIND?+MASK?)
- S6 DT=CONTROLLED CLINICAL TRIAL+CONTROLLED CLINICAL TRIALS!+PLACEBOS /  
DE + SINGLE-BLIND METHOD /DE + CROSS-OVER STUDIES /DE + PLACEBO? + DT=  
COMPARATIVE STUDY+COMPARATIVE STUDY /DE+CONTROL? (1W) (TRIAL?+STUD?)
- S7 DT = CLINICAL TRIAL? + CLINICAL TRIALS! /DE + (PHASE + CLINICAL + PILOT +  
ESCALAT?+DOSE) (2W) (TRIAL?+STUDY+STUDIES) /TI
- S8 COHORT STUDIES! + (RETROSPECTIV? + PROSPECTIV? + LONGITUDIN? + CROSS ()  
SECTION?+COHORT?+FOLLOW () UP+FOLLOWUP) (1W) (STUDY+STUDIES) /TI+  
EPIDEMIOLOGIC STUDIES!
- S9 DT=MULTICENTER STUDY+MULTICENTER STUDIES /DE+ (MULTICENT?+MULTI (W)

CENT?) /TI

S10 CASE-CONTROL STUDIES!+MATCHED-PAIR ANALYSIS/DE+CASE () CONTROL/TI

S11 S1 : S10

S12 CARCINOMA, HEPATOCELLULAR! + (HEPATOCELL? + HAEPATOCELL? + (HEPATO + HAEPATO)) (W) (CELL?? + CELLULA?) (2N) (NEOPLASM? + CANCER? + TUMOR? + TUMOUR?+CARCINOM?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S13 S11\*S12

S14 S13/HUMAN OR (S13 NOT ANIMALS)

S15 S14/ENG

S16 S15 AND UP=20070701 : 20111231

S17 RADIOTHERAPY! + RT / DF + RADIOCHEM? + CHEMORADIO? + IRRADIAT? + RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?

S18 S16\*S17

S19 PROGNOSIS!+PROGNOS?+OUTCOME?+RECURRENCE?+RELAPSE?+REOCCURRENCE?

S20 EFFECACY OR SURVIVAL? OR RESPONSE () (RATE OR RATES) OR LOCAL () CONTROL? OR SAFETY OR ADVERS? (1W) (EFFECT? OR EVENT OR EVENTS) OR TOXICITY OR FEASIBILITY

S21 S19+S20

S22 S18\*S21

S23 S1 : S6

S24 S23/HUMAN OR (S23 NOT ANIMALS)

S25 S24/ENG

S26 S25 AND UP=20070701 : 20111231

S27 ( RADIOTHERAPY! + RT / DF + RADIOCHEM? + CHEMORADIO? + IRRADIAT? + RADIOTHERA?+RADIAT?+BRACHYTHER?+RADIOSURGE?) \*METASTA?

S28 S16\*S27

S29 S26\*S27

S30 METASTA? (4N) (RADIOTHER?+CHEMORADIO?+RADIOCHEM?+IRRADIAT?+RADIAT? +BRACHYTHER?+RADIOSURG?)

S31 S16\*S30

S32 S26\*S30

S33 CENTRAL NERVOUS SYSTEM NEOPLASMS! (L) SECONDARY OR BONE NEOPLASMS! (L) SECONDARY

S34 (BONE? ? OR BRAIN? OR CEREBRAL? OR INTRACEREBRAL?) (4N) METASTA?

S35 S28+S31

S36 (S29+S32) \* (S33+S34)

S37 (BONE? ? OR BRAIN? OR CEREBRAL? OR INTRACEREBRAL?) /TI AND S36

S38 S35+S37

S39 S34/TI AND S36

S40 S39+S35

## [Chapter 8] Post-Treatment Surveillance and Prevention and Treatment of Recurrence

- **CQ52 How should patients be followed up after hepatectomy and percutaneous ablation? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR / DF + (HEPATOCELL? + HAEPATOCELL? + (HEPATO? + HAEPATO? + LIVER?) (W) (CELL?? + CELLULA?)) (2N) (NEOPLASM? + CANCER? + TUMOR? + TUMOUR? + CARCINOM?) / TI + (HEPATOMA? ? + HAEPATOMA? ?) / TI + (HCC + HCCS) / TI \* LIVER NEOPLASMS!

S2 S1 / HUMAN + (S1 NOT ANIMALS)

S3 S2 / ENG

S4 S3 AND PY = > 1982 AND UP = 19830906 : 19900630

S5 S3 AND PY = > 1982 AND UP = 19900630 : 19950630

S6 S3 AND PY = > 1982 AND UP = 19950630 : 20000630

S7 S3 AND PY = > 1982 AND UP = 20000630 : 20050630

S8 S3 AND PY = > 1982 AND UP = 20050630 : 20111231

S9 S4 : S8

S10 DT = REVIEW? OR REVIEW? / TI OR DT = CASE REPORT? OR CASE () REPORT? / TI

S11 S9 NOT S10

S12 DT = META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) / TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? / TI OR DT = PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9 \* S12

S14 S11 + S13

S15 HEPATECTOMY!

S16 LIVER NEOPLASMS (L) SU

S17 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?) / TI

S18 FOLLOWUP OR FOLLOW () UP

S19 S14 \* (S15 + S16 + S17)

S20 S18 \* S19

S21 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?) (4N) (AFTER OR FOLLOW?)

S22 POSTOPERA? OR POSTSURG? OR POSTHEPATEC? OR POSTRESECT? OR POST () (SURGER? OR SURGI? OR OPERAT? OR HEPATECT? OR RESECT?)

S23 S18 / TI \* S19

S24 S18 (3N) (EVALUAT? OR ASSESS? OR INVESTIGAT? OR METHOD? OR SYSTEM? OR ADEQUAT? OR APPROPRIAT? OR OPTIMAL? OR RECOMMEND?)

S25 (S21 + S22) (4N) S18

S26 S20\*S24  
S27 S20\*S25  
S28 (S26+S27) \* (S21+S22) /TI+S23

**CQ52 How should patients be followed up after hepatectomy and percutaneous ablation? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR /DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!  
S2 S1/HUMAN+ (S1 NOT ANIMALS)  
S3 S2/ENG  
S4 S3 AND PY=>1982 AND UP=19830906 : 19900630  
S5 S3 AND PY=>1982 AND UP=19900630 : 19950630  
S6 S3 AND PY=>1982 AND UP=19950630 : 20000630  
S7 S3 AND PY=>1982 AND UP=20000630 : 20050630  
S8 S3 AND PY=>1982 AND UP=20050630 : 20111231  
S9 S4 : S8  
S10 DT=REVIEW? OR REVIEW? /TI OR DT=CASE REPORT? OR CASE () REPORT? /TI  
S11 S9 NOT S10  
S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW? /TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!  
S13 S9\*S12  
S14 S11+S13  
S15 (PEI OR PEIT OR EIT) AND ETHANOL??  
S16 MICROWAVES /DE OR MICROWAVE? (3N) (PERCUTAN? OR COAGULAT?)  
S17 (PMCT OR MCT) AND MICROWAVE?  
S18 ELECTROCOAGULATION! OR RADIO WAVES /DE OR ABLAT?  
S19 RADIOFREQUEN? OR RADIO () FREQUEN? OR RFA  
S20 PEI \* (PERCUTANEOUS?+ETHANOL?) +PEIT+ (PERCUTANEOUS?+TRANSDERMAL?) (2N) (ETHANOL? OR ETHYL () ALCOHOL?)  
S21 PMCT+PERCUTANEOUS? (1W) COAGULAT? (1W) THERAP?  
S22 RFA+ (RADIO (1W) (FREQUENC?+WAVE?) +RADIOFREQUEN?) (2N) ABLAT?  
S23 (LOCAL + TOPICAL + LOCOREGIONAL? OR LOCO () REGIONAL?) (3N) (REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)  
S24 S15 : S23  
S25 S14\*S24  
S26 FOLLOWUP OR FOLLOW () UP  
S27 S25\*S26  
S28 S26/TI\*S27

S29 S26 (3N) (EVALUAT? OR ASSESS? OR INVESTIGAT? OR METHOD? OR SYSTEM? OR ADEQUAT? OR APPROPRIAT? OR OPTIMAL? OR RECOMMEND?)

S30 (PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR REGIONAL? OR TOPICAL?) (4N) S26

S31 S29\*S27

S32 S30\*S27

S33 S28+S31+S32

S34 POST () (RFA OR PEI OR PEIT OR EIT OR PMCT OR MCT OR LOCAL? OR LOCOREGIONAL? OR TOPICAL? OR RADIOFREQUEN? OR ELECTROCOAGU? OR MICROWAVE?)

S35 S33\* (S34+S24/TI)

- **CQ53 What are the effective methods for preventing recurrence after hepatectomy and percutaneous ablation? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY=>1982 AND UP=19830906 : 19900630

S5 S3 AND PY=>1982 AND UP=19900630 : 19950630

S6 S3 AND PY=>1982 AND UP=19950630 : 20000630

S7 S3 AND PY=>1982 AND UP=20000630 : 20050630

S8 S3 AND PY=>1982 AND UP=20050630 : 20111231

S9 S4 : S8

S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S11 S9 NOT S10

S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9\*S12

S14 S11+S13

S15 HEPATECTOMY!

S16 LIVER NEOPLASMS (L) SU

S17 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?) /TI

S18 RECURREN?

S19 NEOPLASM RECURRENCE, LOCAL! (L) PC

S20 (PROGRES? OR RECURREN?) (3N) (PREVEN? OR PROPHYLA?)

S21 S14\* (S15+S16+S17) \*S18

S22 S21 \* (S19+S20)

S23 (S18/TI+S17) AND S22

S24 (PREVEN? OR PROPHYL? OR REDUC? OR DECREAS?) /TI AND S22

S25 S23+S24

- **CQ53 What are the effective methods for preventing recurrence after hepatectomy and percutaneous ablation? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY=>1982 AND UP=19830906 : 19900630

S5 S3 AND PY=>1982 AND UP=19900630 : 19950630

S6 S3 AND PY=>1982 AND UP=19950630 : 20000630

S7 S3 AND PY=>1982 AND UP=20000630 : 20050630

S8 S3 AND PY=>1982 AND UP=20050630 : 20111231

S9 S4 : S8

S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S11 S9 NOT S10

S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9\*S12

S14 S11+S13

S15 (PEI OR PEIT OR EIT) AND ETHANOL??

S16 MICROWAVES/DE OR MICROWAVE? (3N) (PERCUTAN? OR COAGULAT?)

S17 (PMCT OR MCT) AND MICROWAVE?

S18 ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?

S19 RADIOFREQUEN? OR RADIO () FREQUEN? OR RFA

S20 PEI\* (PERCUTANEOUS?+ETHANOL?) +PEIT+ (PERCUTANEOUS?+TRANSDERMAL?) (2N) (ETHANOL? OR ETHYL () ALCOHOL?)

S21 PMCT+PERCUTANEOUS? (1W) COAGULAT? (1W) THERAP?

S22 RFA+ (RADIO (1W) (FREQUENC?+WAVE?) +RADIOFREQUEN?) (2N) ABLAT?

S23 (LOCAL+TOPICAL+LOCOREGIONAL? OR LOCO () REGIONAL?) (3N) (REMED?+THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)

S24 S15 : S23

S25 RECURREN?

S26 NEOPLASM RECURRENCE, LOCAL! (L) PC

S27 (PROGRES? OR RECURREN?) (3N) (PREVEN? OR PROPHYLA?)



S28 S14\*S24\*S25

S29 S28\* (S26+S27)

S30 SURVIV? (3N) (INCREAS? OR PROLONG? OR IMPROV?)

S31 (PREDICT? OR DETECT?) (3N) (PROGRES? OR RECURREN?)

S32 USEFUL? OR EFFECTIVE? OR EFFICAC?

S33 S28\*S30

S34 S28\*S31

S35 TREATMENT OUTCOME/DE

S36 (S33+S34) \* (S32+S35)

S37 S36\* (S24/TI OR S25/TI OR PROVEN? OR PROPHYL? OR REDUC? OR S30/TI)

S38 S29+S37

S39 (S24/TI OR MT/DE OR TU/DE OR S24/MAJ) AND S38

- **CQ54 What are the effective methods for preventing recurrence after liver transplantation? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?)/TI+ (HEPATOMA? ?+HAEPATOMA? ?)/TI+ (HCC+HCCS)/TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY=>1982 AND UP=19830906 : 19900630

S5 S3 AND PY=>1982 AND UP=19900630 : 19950630

S6 S3 AND PY=>1982 AND UP=19950630 : 20000630

S7 S3 AND PY=>1982 AND UP=20000630 : 20050630

S8 S3 AND PY=>1982 AND UP=20050630 : 20111231

S9 S4 : S8

S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI

S11 S9 NOT S10

S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)/TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9\*S12

S14 S11+S13

S15 LIVER TRANSPLANTATION! OR LIVER! (L) TR OR LIVER? (3N) TRANSPLANT?

S16 RECURREN?

S17 NEOPLASM RECURRENCE, LOCAL (L) PC

S18 (PROGRES? OR RECURREN?) (3N) (PREVEN? OR PROPHYLA?)

S19 IMMUNOSUPPRESSIVE AGENTS! (L) TU

S20 SURVIV? (3N) (INCREAS? OR PROLONG? OR IMPROV?)

S21 (PREDICT? OR DETECT?) (3N) (PROGRES? OR RECURREN?)

S22 USEFUL? OR EFFECTIVE? OR EFFICAC?

S23 TREATMENT OUTCOME/DE

S24 S14\*S15\*S16

S25 S24\* (S17+S18)

S26 S24\* (S19+S20+S21)

S27 S26\* (S22+S23+S20/TI)

S28 S25+S27

S29 LIVER TRANSPLANTATION! / MAJ OR LIVER TRANSPLANTATION! ( L ) MT OR TRANSPLANT?/TI

S30 S29\*S28

- **CQ55 What are the effective treatments against recurrence after hepatectomy? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!

S2 S1/HUMAN+ (S1 NOT ANIMALS)

S3 S2/ENG

S4 S3 AND PY=>1982 AND UP=19830906 : 19900630

S5 S3 AND PY=>1982 AND UP=19900630 : 19950630

S6 S3 AND PY=>1982 AND UP=19950630 : 20000630

S7 S3 AND PY=>1982 AND UP=20000630 : 20050630

S8 S3 AND PY=>1982 AND UP=20050630 : 20111231

S9 S4 : S8

S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE ( ) REPORT?/TI

S11 S9 NOT S10

S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!

S13 S9\*S12

S14 S11+S13

S15 HEPATECTOMY!

S16 LIVER NEOPLASMS (L) SU

S17 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTEATOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?) /TI

S18 (HEPATECTOM? OR LOBECTOM? OR SEGMENTECTOM? OR SUBSEGMENTECTOM? OR RESECT? OR SURGER? OR SURGI? OR OPERAT? OR TRANSECT? OR REMOV?) (4N) (AFTER OR FOLLOW?)

S19 POSTOPERA? OR POSTSURG? OR POSTHEPATEC? OR POSTRESECT? OR POST ( ) (SURGER? OR SURGI? OR OPERAT? OR HEPATECT? OR RESECT?)

S20 (S18+S19) (4N) RECURREN?  
 S21 S14\* (S15+S16+S17)  
 S22 S20\*S21  
 S23 NEOPLASM RECURRENCE, LOCAL! (L) (TH+DT+RT+SU)  
 S24 S22\*S23  
 S25 S20/TI\*S22  
 S26 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?) /TI  
 S27 S26 AND S25  
 S28 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR EFFICIEN? OR SUPERIOR?) (5N) S20  
 S29 S25\*S28  
 S30 RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!  
 S31 TU/DE  
 S32 S25\*S30\*S31  
 S33 S24\*S20/TI  
 S34 S24+S27+S29+S32+S33

- **CQ56 What treatments are effective against recurrence after percutaneous ablation? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+ HAEPATO?+LIVER?)) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR? +TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS) /TI\*LIVER NEOPLASMS!  
 S2 S1/HUMAN+ (S1 NOT ANIMALS)  
 S3 S2/ENG  
 S4 S3 AND PY=>1982 AND UP=19830906 : 19900630  
 S5 S3 AND PY=>1982 AND UP=19900630 : 19950630  
 S6 S3 AND PY=>1982 AND UP=19950630 : 20000630  
 S7 S3 AND PY=>1982 AND UP=20000630 : 20050630  
 S8 S3 AND PY=>1982 AND UP=20050630 : 20111231  
 S9 S4 : S8  
 S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI  
 S11 S9 NOT S10  
 S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?) /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!  
 S13 S9\*S12  
 S14 S11+S13  
 S15 (PEI OR PEIT OR EIT) AND ETHANOL??  
 S16 MICROWAVES/DE OR MICROWAVE? (3N) (PERCUTAN? OR COAGULAT?)

S17 (PMCT OR MCT) AND MICROWAVE?

S18 ELECTROCOAGULATION! OR RADIO WAVES/DE OR ABLAT?

S19 RADIOFREQUEN? OR RADIO () FREQUEN? OR RFA

S20 PEI\* (PERCUTANEOUS?+ETHANOL?) +PEIT+ (PERCUTANEOUS?+TRANSDERMAL?)  
(2N) (ETHANOL? OR ETHYL () ALCOHOL?)

S21 PMCT+PERCUTANEOUS? (1W) COAGULAT? (1W) THERAP?

S22 RFA+ (RADIO (1W) (FREQUENC?+WAVE?) +RADIOFREQUEN?) (2N) ABLAT?

S23 (LOCAL+TOPICAL+LOCOREGIONAL? OR LOCO () REGIONAL?) (3N) (REMEDI?+  
THERAP?+TREATMENT?+CENTESIS+NEEDL?+NYXIS+PUNCTURE?+ACUPUNCTURE?)

S24 S15 : S23

S25 S14\*S24

S26 (PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR MICROWAVE? OR  
ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR LOCAL? OR  
REGIONAL? OR TOPICAL?) (4N) (AFTER OR FOLLOW?)

S27 POST () (RFA OR PEI OR PEIT OR EIT OR PMCT OR MCT OR LOCAL? OR LOCOREGIONAL?  
OR TOPICAL? OR RADIOFREQUEN? OR ELECTROCOAGU? OR MICROWAVE?)

S28 (S26+S27) (4N) RECURREN?

S29 NEOPLASM RECURRENCE, LOCAL! (L) (TH+DT+RT+SU)

S30 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR  
EFFICIEN? OR SUPERIOR?) /TI

S31 S25\*S28

S32 S29\*S31

S33 S30\*S31

S34 RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!

S35 TU/DE

S36 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR  
EFFICIEN? OR SUPERIOR?) (4N) S28

S37 S31\*S36

S38 S31\*S34\*S35

S39 (AFTER OR FOLLOW?) (1W) (PEI OR PEIT OR EIT OR ETHANOL? OR PMCT OR MCT OR  
MICROWAVE? OR ELECTROCOAGU? OR RFA OR RADIOFREQUEN? OR LOCOREGION? OR  
LOCAL? OR REGIONAL? OR TOPICAL?)

S40 RECURREN? (3W) S39

S41 S40\*S31\* (S29+S30)

S42 S32+S33+S37+S38+S41

- **CQ57 What treatments are effective against recurrence after liver transplantation? [MEDLINE]**

S1 CARCINOMA, HEPATOCELLULAR/DF+ (HEPATOCELL?+HAEPATOCELL?+ (HEPATO?+  
HAEPATO?+LIVER?) (W) (CELL??+CELLULA?)) (2N) (NEOPLASM?+CANCER?+TUMOR?  
+TUMOUR?+CARCINOM?) /TI+ (HEPATOMA? ?+HAEPATOMA? ?) /TI+ (HCC+HCCS)

/TI\*LIVER NEOPLASMS!  
 S2 S1/HUMAN+ (S1 NOT ANIMALS)  
 S3 S2/ENG  
 S4 S3 AND PY=>1982 AND UP=19830906 : 19900630  
 S5 S3 AND PY=>1982 AND UP=19900630 : 19950630  
 S6 S3 AND PY=>1982 AND UP=19950630 : 20000630  
 S7 S3 AND PY=>1982 AND UP=20000630 : 20050630  
 S8 S3 AND PY=>1982 AND UP=20050630 : 20111231  
 S9 S4 : S8  
 S10 DT=REVIEW? OR REVIEW?/TI OR DT=CASE REPORT? OR CASE () REPORT?/TI  
 S11 S9 NOT S10  
 S12 DT=META-ANALYSIS OR META ANALYSIS OR (META (1W) ANALY? OR METAANAL?)  
 /TI OR SYSTEMATIC REVIEW! OR SYSTEMATIC (1W) REVIEW?/TI OR DT=PRACTICE  
 GUIDELINE OR PRACTICE GUIDELINES AS TOPIC!  
 S13 S9\*S12  
 S14 S11+S13  
 S15 LIVER TRANSPLANTATION! OR LIVER! (L) TR OR LIVER? (3N) TRANSPLANT?  
 S16 S14\*S15  
 S17 NEOPLASM RECURRENCE, LOCAL! (L) (TH+DT+RT+SU)  
 S18 RECURREN? (4N) ((FOLLOW? OR AFTER) (4N) TRANSPLAN? OR POSTTRANSPLAN? OR  
 POST () TRANSPLAN?)  
 S19 S16\*S17  
 S20 S16\*S18/TI  
 S21 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR  
 EFFICIEN? OR SUPERIOR?) /TI  
 S22 S20 AND S21  
 S23 (TREAT? OR THERAP? OR USEFUL? OR BENEFIT? OR EFFECTIVE? OR EFFICAC? OR  
 EFFICIEN? OR SUPERIOR?) (5N) S18  
 S24 S23\*S16  
 S25 RECURREN?/TI OR NEOPLASM RECURRENCE, LOCAL!  
 S26 TU/DE  
 S27 S16\*S25\*S26  
 S28 S19+S22+S24+S27